共 7 条
Antipsychotic switching versus augmentation among early non-responders to risperidone or olanzapine in acute-phase schizophrenia
被引:19
|作者:
Hatta, Kotaro
[1
,15
]
Otachi, Taro
[2
]
Fujita, Kiyoshi
[3
]
Morikawa, Fumiyoshi
[4
]
Ito, Shin
[5
]
Tomiyama, Hirofumi
[6
]
Abe, Takayuki
[7
]
Sudo, Yasuhiko
[8
]
Takebayashi, Hiroshi
[9
]
Yamashita, Toru
[10
]
Katayama, Shigemasa
[11
]
Nakase, Reiko
[12
]
Shirai, Yutaka
[13
]
Usui, Chie
[1
]
Nakamura, Hiroyuki
[14
]
Ito, Hiroto
[15
]
Hirata, Toyoaki
[7
]
Sawa, Yutaka
[16
]
机构:
[1] Juntendo Univ, Dept Psychiat, Nerima Hosp, Tokyo 1778521, Japan
[2] Gunma Psychiat Med Ctr, Dept Psychiat, Isesaki, Japan
[3] Okehazama Hosp, Dept Psychiat, Toyoake, Aichi, Japan
[4] Asahikawa Keisenkai Hosp, Dept Psychiat, Asahikawa, Hokkaido, Japan
[5] Kumpukai Yamada Hosp, Dept Psychiat, Tokyo, Japan
[6] Natl Hosp Org Hizen Psychiat Ctr, Dept Psychiat, Yoshinogari, Japan
[7] Chiba Psychiat Med Ctr, Dept Psychiat, Chiba, Japan
[8] Tosa Hosp, Dept Psychiat, Kochi, Japan
[9] Saitama Prefectural Psychiat Hosp, Dept Psychiat, Ina, Saitama, Japan
[10] Yamanashi Prefectural Kita Hosp, Dept Psychiat, Nirasaki, Japan
[11] Seijin Hosp, Dept Psychiat, Tokyo, Japan
[12] Mie Prefectural Mental Med Ctr, Dept Psychiat, Tsu, Mie, Japan
[13] Hyogo Prefecture Kofu Hosp, Dept Psychiat, Kobe, Hyogo, Japan
[14] Kanazawa Univ, Dept Environm & Prevent Med, Grad Sch Med Sci, Kanazawa, Ishikawa, Japan
[15] Natl Ctr Neurol & Psychiat, Dept Social Psychiat, Kodaira, Tokyo, Japan
[16] Sawa Hosp, Dept Psychiat, Osaka, Japan
关键词:
Early response;
Combination;
Add-on;
Polypharmacy;
Emergency;
Randomized clinical trial;
PHARMACOKINETICS;
MEDICATIONS;
MONOTHERAPY;
SCALE;
D O I:
10.1016/j.schres.2014.07.015
中图分类号:
R749 [精神病学];
学科分类号:
100205 ;
摘要:
Purpose: We examined whether augmentation with olanzapine would be superior to switching to olanzapine among early non-responders (ENRs) to risperidone, and whether augmentation with risperidone would be superior to switching to risperidone among ENRs to olanzapine. We performed a rater-blinded, randomized clinical trial at psychiatric emergency sites. Eligible patients were newly admitted patients with acute schizophrenia. ENRs to the initial antipsychotic (Clinical Global Impressions-Improvement Scale: >= 4 at 2 weeks) were allocated to receive either augmentation with or switching to the other antipsychotic (RIS + OLZ vs. RIS-OLZ; OLZ + RIS vs. OLZ-RIS). Results: Sixty patients who completed 2 weeks of risperidone treatment were divided into 33 early responders (RIS-ER) and 27 ENRs (RIS + OLZ, n = 14; RIS-OLZ, n = 13). Although time to treatment discontinuation for any cause was significantly shorter in RIS + OLZ group (54.1 days [95% confidence interval, 41.3-67.0]) than in RIS-ER group (68.7 [61.2-76.2]; P = 0.050), it was not significantly shorter in RIS-OLZ group (58.5 [43.1-73.9]) than in RIS-ER group (P = 0.19). Sixty patients who completed 2 weeks of olanzapine treatment were divided into 36 early responders (OLZ-ER) and 24 ENRs (OLZ + RIS, n = 11; OLZ-RIS, n = 13). Although time to treatment discontinuation for any cause was significantly shorter in OLZ-RIS group (56.1 days [40.7-71.5]) than in OLZ-ER group (74.9 [68.5-81.3]; P = 0.008), it was not significantly shorter in OLZ + RIS group (64.6 [49.6-79.6]) than in OLZ-ER group (P= 0.20). Conclusion: Despite the lack of pharmacokinetic investigation of dose adequacy in this study, it is possible that switching to olanzapine among ENRs to risperidone might have a small advantage over augmentation with olanzapine, while augmentation with risperidone might have a small advantage over switching to risperidone among ENRs to olanzapine. Further research is required before itwould be appropriate tomodify routine practice in the direction of these findings. (C) 2014 The Authors. Published by Elsevier B. V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
引用
收藏
页码:213 / 222
页数:10
相关论文